Cambridge Investment Research Advisors, Inc. Tarsus Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 25,075 shares of TARS stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,075
Previous 22,975
9.14%
Holding current value
$1.17 Million
Previous $624,000
32.21%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TARS
# of Institutions
170Shares Held
43.3MCall Options Held
484KPut Options Held
4.1K-
Rtw Investments, LP New York, NY3.41MShares$159 Million1.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$152 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$114 Million2.89% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$105 Million6.32% of portfolio
-
Morgan Stanley New York, NY2.21MShares$103 Million0.01% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.24B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...